Core Viewpoint - The announcement highlights the results of various clinical trials for LuX-Valve Plus, JensClip, and Ken-Valve, showcasing advancements in transcatheter heart valve technologies presented at the TCT2025 conference [1] Group 1: Clinical Trial Results - LuX-Valve Plus's global multicenter clinical trial (TRINITY) reported six-month follow-up results for transcatheter tricuspid valve replacement (TTVR) [1] - JensClip's one-year follow-up results for transcatheter mitral valve repair (TMVr) were shared, along with evidence of its effectiveness in challenging cases [1] - Ken-Valve's one-year follow-up results for transcatheter aortic valve replacement (TAVR) were also presented, including outcomes in challenging case applications [1] Group 2: Conference Presentation - The results were presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT2025) conference held in San Francisco [1]

Core Viewpoint - The announcement highlights the results of multiple clinical trials for various cardiovascular systems developed by the company, showcasing advancements in minimally invasive heart valve procedures [1] Group 1: Clinical Trial Results - The TRINITY trial results for the LuX-Valve Plus system, focusing on transcatheter tricuspid valve replacement (TTVR), were presented, emphasizing the six-month follow-up outcomes [1] - The one-year follow-up results for the JensClip system, which is designed for transcatheter mitral valve repair (TMVr), were also shared, along with insights on challenging case applications [1] - Additionally, the one-year follow-up results for the Ken-Valve system, used for transcatheter aortic valve replacement (TAVR), were discussed, including its performance in challenging cases [1] Group 2: Event Details - The results were presented at the TCT 2025 conference held in San Francisco, indicating the company's active participation in significant cardiovascular academic events [1]